Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Molecular Cancer|December 29, 2022
Targeting SOST using a small-molecule compound retards breast cancer bone metastasisLisha Sun, Yixiao Zhang, Guanglei Chen, et al.
Optics Express|May 5, 2017
Enhanced optical sensitivity of molybdenum diselenide (MoSe2) coated side polished fiber for humidity sensingTenghui Ouyang, Limin Lin, Kai Xia, et al.
Signal Transduction and Targeted Therapy|March 26, 2025
Molecular classification of hormone receptor-positive /HER2-positive breast cancer reveals potential neoadjuvant therapeutic strategiesChao Liu, Lisha Sun, Nan Niu, et al.
Elife|July 28, 2025
Efficacy and safety of neoadjuvant stereotactic body radiation therapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer: A prospective pilot studyYu Zhang, Shuo Cao, Nan Niu, et al.
Elife|December 22, 2023
Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot studyGuanglei Chen, Xi Gu, Jinqi Xue, et al.
Annals of Surgical Oncology|June 25, 2025
Surgical and Oncologic Outcomes of Tumescence and Sharp Dissection Versus Electrocautery Dissection in Minimal-Access Nipple-Sparing Mastectomy with Immediate Prosthesis Breast Reconstruction: A Real-World Retrospective Cohort StudyXinyu Ou, Zhihan Liu, Caigang Liu, et al.
The Lancet Regional Health. Western Pacific|October 13, 2025
Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trialJinqi Xue, Huilian Shan, Fang Qiu, et al.
Medcomm|March 12, 2024
A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancerShiwen Huo, Jinqi Xue, Shuo Wang, et al.
Nature Communications|July 2, 2025
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trialNan Niu, Jinqi Xue, Guanglei Chen, et al.
Nature Communications|November 17, 2022
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancerNan Niu, Fang Qiu, Qianshi Xu, et al.
Pageof 8